David Schilansky, CEO and Co-founder of Home Biosciences also believes M&A activity will be intense in 2024 but, in his opinion, it will also be a year when substantial capital will be raised:  “Investors have money that needs to be put to work and will fear losing out on the ongoing M&A wave.
David Schilansky, CEO and Co-founder of Home Biosciences also believes M&A activity will be intense in 2024 but, in his opinion, it will also be a year when substantial capital will be raised:  “Investors have money that needs to be put to work and will fear losing out on the ongoing M&A wave. If you look at 2021-2023 transactions, the companies that were acquired had already demonstrated good data or products. But now some pharma are starting again to buy companies with data in front of them and take on a bit more risk in dealmaking to pick up the highest quality opportunities at affordable prices.”